Dr Thomas P. Monath, Md

Biography

 Dr. Monath is a Chief Science Officer and Chief Operating Officer of BioProtection Systems/NewLink Genetics Corp (NASDAQ: NLNK), where he is engaged in development of Ebola vaccine and new vaccines against other infectious diseases.  In his current position he is responsible for the development of the recombinant vesicular stomatitis-Ebola vaccine that has recently shown 100% efficacy in a Phase 3 trial in Guinea. The vaccine is exclusively licensed from NewLink to Merck. Monath’s expertise and experience cut across discovery research, process and analytical development, manufacturing, preclinical and clinical development, and regulatory affairs. Monath is also a Venture Partner at Kleiner Perkins Caufield & Byers and is a Director of Vaxinnate Inc., Sentinext plc, Rapid Micro Biosystems Inc, and US Biologics Inc.

Research Interest

 Research Interest On Pharmacotherapeutics